APO Research
Talk to an analyst

APO RESEARCH · REPORT

Conjugate Vaccine

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Selected research

Market Outlook & Growth Opportunities

Global Conjugate Vaccine Market Outlook and Growth Opportunities 2026

27 December 2025195 pages

Choose your research edition.

Industry ResearchConjugate Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Conjugate Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Conjugate Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Conjugate Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.

This report provides an overview of the global Conjugate Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Conjugate Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Conjugate Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Conjugate Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Conjugate Vaccine Segment by Company

Pfizer

GSK

Sanofi

Merck

Walvax Biotechnology

Royal (Wuxi) Bio-Pharmaceutical

Bharat Biotech

Zhifei Biologic

Conjugate Vaccine Segment by Type

Hib Vaccine

Meningococcal Vaccine

Pneumococcal Vaccine

Others

Conjugate Vaccine Segment by End Users

Children

Adult

Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Conjugate Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Conjugate Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Conjugate Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Conjugate Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Conjugate Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Conjugate Vaccine industry.

Chapter 3: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Conjugate Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Conjugate Vaccine Industry Trends Table 2. Conjugate Vaccine Industry Drivers Table 3. Conjugate Vaccine Industry Opportunities and Challenges Table 4. Conjugate Vaccine Industry Restraints Table 5. Global Conjugate Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Conjugate Vaccine Revenue Share by Company (2021-2026) Table 7. Global Conjugate Vaccine Sales Volume by Company (Million Unit) & (2021-2026) Table 8. Global Conjugate Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Conjugate Vaccine Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Conjugate Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Conjugate Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Conjugate Vaccine Company, Product Type & Application Table 13. Global Conjugate Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Conjugate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hib Vaccine Table 18. Significant Companies of Meningococcal Vaccine Table 19. Significant Companies of Pneumococcal Vaccine Table 20. Significant Companies of Others Table 21. Global Conjugate Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (Million Unit) Table 22. Global Conjugate Vaccine Sales Volume by Type (2021-2026) & (Million Unit) Table 23. Global Conjugate Vaccine Sales Volume by Type (2027-2032) & (Million Unit) Table 24. Global Conjugate Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Conjugate Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Conjugate Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Conjugate Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Conjugate Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Conjugate Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Conjugate Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Children Table 32. Significant Companies of Adult Table 33. Global Conjugate Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (Million Unit) Table 34. Global Conjugate Vaccine Sales Volume by Application (2021-2026) & (Million Unit) Table 35. Global Conjugate Vaccine Sales Volume by Application (2027-2032) & (Million Unit) Table 36. Global Conjugate Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Conjugate Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Conjugate Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Conjugate Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Conjugate Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Conjugate Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Conjugate Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Million Unit) Table 44. Global Conjugate Vaccine Sales by Region (2021-2026) & (Million Unit) Table 45. Global Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Conjugate Vaccine Sales by Region (2027-2032) & (Million Unit) Table 47. Global Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Conjugate Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Conjugate Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Conjugate Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Conjugate Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Conjugate Vaccine Market Average Price (USD/Unit) by Region (2021-2026) Table 54. Global Conjugate Vaccine Market Average Price (USD/Unit) by Region (2027-2032) Table 55. Global Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (Million Unit) Table 56. Global Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 58. Global Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 60. Global Conjugate Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Conjugate Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Conjugate Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Conjugate Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Conjugate Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. Pfizer Conjugate Vaccine Product Portfolio Table 69. Pfizer Recent Development Table 70. GSK Company Information Table 71. GSK Business Overview Table 72. GSK Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. GSK Conjugate Vaccine Product Portfolio Table 74. GSK Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Sanofi Conjugate Vaccine Product Portfolio Table 79. Sanofi Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Merck Conjugate Vaccine Product Portfolio Table 84. Merck Recent Development Table 85. Walvax Biotechnology Company Information Table 86. Walvax Biotechnology Business Overview Table 87. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Walvax Biotechnology Conjugate Vaccine Product Portfolio Table 89. Walvax Biotechnology Recent Development Table 90. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 91. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 92. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio Table 94. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 95. Bharat Biotech Company Information Table 96. Bharat Biotech Business Overview Table 97. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Bharat Biotech Conjugate Vaccine Product Portfolio Table 99. Bharat Biotech Recent Development Table 100. Zhifei Biologic Company Information Table 101. Zhifei Biologic Business Overview Table 102. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Zhifei Biologic Conjugate Vaccine Product Portfolio Table 104. Zhifei Biologic Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Conjugate Vaccine Distributors List Table 108. Conjugate Vaccine Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Conjugate Vaccine Product Image Figure 2. Global Conjugate Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Conjugate Vaccine Sales (2021-2032) & (Million Unit) Figure 5. Global Conjugate Vaccine Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Conjugate Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hib Vaccine Image Figure 10. Meningococcal Vaccine Image Figure 11. Pneumococcal Vaccine Image Figure 12. Others Image Figure 13. Global Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (Million Unit) Figure 14. Global Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Conjugate Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Conjugate Vaccine Sales Value Share by Type (2021-2032) Figure 19. Children Image Figure 20. Adult Image Figure 21. Global Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (Million Unit) Figure 22. Global Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Conjugate Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Conjugate Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Million Unit) Figure 28. Global Conjugate Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Conjugate Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Conjugate Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Conjugate Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Meningococcal Vaccine
  • Pneumococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal (Wuxi) Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Conjugate Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Conjugate Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Conjugate Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Conjugate Vaccine Market Dynamics
  1. 2.1 Conjugate Vaccine Industry Trends
  2. 2.2 Conjugate Vaccine Industry Drivers
  3. 2.3 Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Conjugate Vaccine Industry Restraints
3 Conjugate Vaccine Market by Company
  1. 3.1 Global Conjugate Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Conjugate Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Conjugate Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Conjugate Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Conjugate Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Conjugate Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Conjugate Vaccine Company Product Type and Application
  8. 3.8 Global Conjugate Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Conjugate Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Conjugate Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Conjugate Vaccine Market by Type
  1. 4.1 Conjugate Vaccine Type Introduction
  2. 4.1.1 Hib Vaccine
  3. 4.1.2 Meningococcal Vaccine
  4. 4.1.3 Pneumococcal Vaccine
  5. 4.1.4 Others
  6. 4.2 Global Conjugate Vaccine Sales Volume by Type
  7. 4.2.1 Global Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Conjugate Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Conjugate Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Conjugate Vaccine Sales Value by Type
  11. 4.3.1 Global Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Conjugate Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Conjugate Vaccine Sales Value Share by Type (2021-2032)
5 Conjugate Vaccine Market by Application
  1. 5.1 Conjugate Vaccine Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Conjugate Vaccine Sales Volume by Application
  5. 5.2.1 Global Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Conjugate Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Conjugate Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Conjugate Vaccine Sales Value by Application
  9. 5.3.1 Global Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Conjugate Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Conjugate Vaccine Sales Value Share by Application (2021-2032)
6 Conjugate Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Conjugate Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Conjugate Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Conjugate Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Conjugate Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Conjugate Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Conjugate Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Conjugate Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Conjugate Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Conjugate Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Conjugate Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Conjugate Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Conjugate Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Conjugate Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
7 Conjugate Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Conjugate Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Conjugate Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Conjugate Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Conjugate Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Conjugate Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Conjugate Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Conjugate Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Conjugate Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Conjugate Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Conjugate Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Walvax Biotechnology
  26. 8.5.1 Walvax Biotechnology Company Information
  27. 8.5.2 Walvax Biotechnology Business Overview
  28. 8.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Walvax Biotechnology Conjugate Vaccine Product Portfolio
  30. 8.5.5 Walvax Biotechnology Recent Developments
  31. 8.6 Royal (Wuxi) Bio-Pharmaceutical
  32. 8.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  33. 8.6.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  34. 8.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio
  36. 8.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  37. 8.7 Bharat Biotech
  38. 8.7.1 Bharat Biotech Company Information
  39. 8.7.2 Bharat Biotech Business Overview
  40. 8.7.3 Bharat Biotech Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bharat Biotech Conjugate Vaccine Product Portfolio
  42. 8.7.5 Bharat Biotech Recent Developments
  43. 8.8 Zhifei Biologic
  44. 8.8.1 Zhifei Biologic Company Information
  45. 8.8.2 Zhifei Biologic Business Overview
  46. 8.8.3 Zhifei Biologic Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Zhifei Biologic Conjugate Vaccine Product Portfolio
  48. 8.8.5 Zhifei Biologic Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Conjugate Vaccine Value Chain Analysis
  2. 9.1.1 Conjugate Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Conjugate Vaccine Sales Mode & Process
  6. 9.2 Conjugate Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Conjugate Vaccine Distributors
  9. 9.2.3 Conjugate Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst